Company Overview
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Boston, Massachusetts. The company is developing a new class of precision small molecule medicines for neurological and psychiatric disorders by targeting Receptor-Associated Proteins (RAPs) — a family of proteins that modulate the function of ion channels in the brain. Rapport''s lead program, RAP-219, is an investigational small molecule that selectively inhibits TARP-gamma-8-containing AMPA receptors (AMPARs) — a receptor subtype concentrated in the hippocampus and limbic system — for the treatment of focal onset seizures (focal epilepsy) and other CNS conditions driven by hyperexcitability in these circuits.
Business Model & Competitive Advantage
Rapport completed a $174 million initial public offering on Nasdaq in June 2024, listing under the ticker symbol RAPP. The IPO included 9.2 million shares at $17.00 per share and a concurrent private placement. The company ended the third quarter of 2025 with approximately $513 million in cash, cash equivalents, and short-term investments — sufficient to fund planned operations into the second half of 2029. Rapport also signed a Greater China collaboration agreement with Tenacia, including a $20 million upfront payment and up to approximately $308 million in additional milestones, validating RAP-219''s international commercial potential. The company initiated a Phase 3 program for RAP-219 in focal onset seizures in Q2 2026.
Competitive Landscape 2025–2026
Rapport''s scientific foundation is built on a precision medicine framework: rather than broadly suppressing neuronal activity (the mechanism of most existing antiepileptic drugs), RAP-219 targets a specific AMPAR subtype expressed in the circuits that generate seizures — theoretically offering efficacy with a more favorable side effect profile. The company''s pipeline extends beyond epilepsy to other AMPAR-mediated neurological conditions. Rapport competes in the CNS precision medicine space with companies like Praxis Precision Medicine, Xenon Pharmaceuticals, and Cerevel Therapeutics (acquired by AbbVie) for ion channel-targeting neurological therapeutics.
Key Differentiators
Emerging Innovator
Rapport Therapeutics is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Compare Rapport Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Rapport Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Rapport Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Rapport Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →